Skip to main content

Management of treatment nonresponse

  • Chapter
  • 1549 Accesses

Abstract

Inadequate treatment response is unfortunately a common problem. Approximately 50–70% of patients gain significant benefit from treatment but, of these, not all will have symptomatic remission [1]. An approximate rule of thirds applies, with a third achieving remission, a third being significantly better but not symptom free with partial remission, and a third remaining depressed. These proportions depend on the duration of follow-up and the nature of the population being studied. Consideration of next-step treatments is therefore extremely important and a pessimist might say that the next step should be planned at the time of the first step. It is certainly important to plan treatment in the knowledge that further steps might be needed.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kennedy N, Foy K. The impact of residual symptoms on outcome of major depression. Curr Psychiatry Rep 2005; 7: 441–446.

    Article  PubMed  Google Scholar 

  2. Anderson I, Ferrier I, Baldwin R, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22:343–396.

    Article  PubMed  CAS  Google Scholar 

  3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905–1917.

    Article  PubMed  Google Scholar 

  4. Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–1917.

    Article  PubMed  Google Scholar 

  5. Anderson IM. Drug treatment of depression: reflections on the evidence. Adv Psychiatr Treat 2003; 9: 11–20.

    Article  Google Scholar 

  6. Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255:387–400.

    Article  PubMed  Google Scholar 

  7. Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 2008; 59:116–122.

    Article  Google Scholar 

  8. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331–336.

    Article  PubMed  CAS  Google Scholar 

  9. Ruhe HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006; 67:1836–1855.

    Article  PubMed  CAS  Google Scholar 

  10. Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines, 9th edition. London: Informa Healthcare, 2007.

    Google Scholar 

  11. Rojo JE, Ros S, Aguera L, et al. Combined antidepressants: clinical experience. Acta Psychiatr Scand 2005; 112(Suppl 428):25–31.

    Article  Google Scholar 

  12. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68:935–940.

    Article  PubMed  CAS  Google Scholar 

  13. Papakostas GI, Shelton RC, Smith J, et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a metaanalysis. J Clin Psychiatry 2007; 68:826–831.

    Article  PubMed  CAS  Google Scholar 

  14. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007; 164:739–752.

    Article  PubMed  Google Scholar 

  15. Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 1999; 56:829–835.

    Article  PubMed  CAS  Google Scholar 

  16. Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry 2004; 61:714–719.

    Google Scholar 

  17. Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997; 54:1009–1015.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Current Medicine Group Ltd, a part of Springer Science+Business Media

About this chapter

Cite this chapter

Anderson, I.M. (2009). Management of treatment nonresponse. In: Handbook of Depression. Springer, Tarporley. https://doi.org/10.1007/978-1-907673-24-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-907673-24-5_7

  • Publisher Name: Springer, Tarporley

  • Print ISBN: 978-1-908517-24-1

  • Online ISBN: 978-1-907673-24-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics